| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Pyrimethamine with sulfadoxine |
Is a |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Poisoning by pyrimethamine |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Accidental pyrimethamine poisoning |
Causative agent (attribute) |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Intentional pyrimethamine poisoning |
Causative agent (attribute) |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| intoxication par la pyriméthamine d'intention indéterminée |
Causative agent (attribute) |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine adverse reaction |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Allergy to pyrimethamine |
Causative agent (attribute) |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Pyrimethamine overdose |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Accidental pyrimethamine overdose |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Intentional pyrimethamine overdose |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| surdose de pyriméthamine d'intention indéterminée |
Causative agent (attribute) |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely dapsone 100 milligram and pyrimethamine 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Pyrimethamine 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Pyrimethamine + sulfadoxine 25mg/500mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Product containing pyrimethamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing dapsone and pyrimethamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing pyrimethamine and sulfadoxine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
|
| Accidental pyrimethamine poisoning |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Intentional pyrimethamine poisoning |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Allergy to pyrimethamine |
Causative agent (attribute) |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine- and sulfadoxine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely dapsone 100 milligram and pyrimethamine 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely dapsone 100 milligram and pyrimethamine 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
2 |
| Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
2 |
| Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
2 |
| Pyrimethamine 25 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine 25 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely dapsone 100 milligram and pyrimethamine 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Dapsone- and pyrimethamine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine 25 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely dapsone 100 milligram and pyrimethamine 12.5 milligram/1 each conventional release oral tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine 25 mg and sulfadoxine 500 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing only dapsone and pyrimethamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing only pyrimethamine and sulfadoxine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine and sulfadoxine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Pyrimethamine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Dapsone and pyrimethamine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely pyrimethamine 12.5 milligram and sulfadoxine 250 milligram/1 each tablet for conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Pyrimethamine (substance) |
Inferred relationship |
Some |
1 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]